Evidence map›Paper›PMID 34829775›Full record

ArticleBiomedicines2021

Evaluation of Macular Retinal Vessels and Histological Changes in Two Cases of COVID-19.

Maria Hernandez, Jorge González-Zamora, Sergio Recalde, Maite Moreno-Orduña, Valentina Bilbao-Malavé, Manuel Saenz de Viteri, Manuel F Landecho, Patricia Fernandez-Robredo, Alfredo García-Layana

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. COVID-19 Related Acute Macular Neuroretinopathy (AMN): A Case Series.International medical case reports journal · 2023
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Maria HernandezRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Jorge González-ZamoraRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Sergio RecaldeRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-9328-9725
Maite Moreno-OrduñaRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Valentina Bilbao-MalavéRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Manuel Saenz de ViteriRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-9375-4535
Manuel F LandechoCOVID-19 Unit, Clínica Universidad de Navarra, 31008 Pamplona, Spain.ORCID 0000-0003-3234-8805
Patricia Fernandez-RobredoRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Alfredo García-LayanaRetinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.
Navarre Institute of Health Research · ESClinica Universidad de Navarra · ES

Funding

Fundación Jesús de Gangoiti BarreraFundación Multiópticas CUN 2019Instituto de Salud Carlos III/European Regional Development Fund (ERDF)OFTARED: Enfermedades oculares: "Prevención, detección precoz, tratamiento y rehabilitación de las patologías oculares RD16/0008/0011
6 · The paper itself

Abstract

The purpose of this study was to assess vascular and histological alterations in two COVID-19 and three control post-mortem retinas. The macular areas of flat-mounted samples were processed for immunofluorescence. Lectin and collagen IV positive vessels were captured under confocal microscopy, and endothelium loss and tortuosity were analyzed. Expression of ACE2 (angiotensin-converting enzyme 2) (the receptor for SARS-CoV-2), Iba1 (ionized calcium-binding adaptor molecule 1) and GFAP (glial fibrillary acidic protein) were quantified in retinal sections. The number of lectin vessels in COVID-19 retinas decreased by 27% compared to the control (

Indexed as

ACE2COVID-19maculamicrogliaretinaSARS-CoV-2tortuosityvasculature

Identifiers

PMID34829775
PMCPMC8615149
OpenAlexW3211324998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.